<DOC>
	<DOCNO>NCT00087581</DOCNO>
	<brief_summary>This three-arm study evaluate efficacy safety various dose regimen MMF combine various dose regimen calcineurin inhibitor ( CNI ) , either cyclosporine tacrolimus , participant undergo kidney transplantation . Participants randomize one three dose regimen receive concentration-controlled MMF reduce CNI , concentration-controlled MMF standard CNI , fixed-dose MMF standard CNI . Participants follow 20-24 month randomization .</brief_summary>
	<brief_title>Study Therapeutic Monitoring Mycophenolate Mofetil ( MMF/CellCept ) After Kidney Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Benzocaine</mesh_term>
	<criteria>Males female 1375 year age Single organ recipient ( kidney ) living ( related unrelated ) cadaveric heartbeating donor Receiving first second kidney transplant Immunosuppressive therapy ( except 48 hour prior transplantation corticosteroid treatment ) within previous 28 day first transplant 3 month second transplant History malignancy last 5 year ( except successfully treat localized nonmelanoma skin cancer )</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>